Publications by authors named "D van Vliet"
Article Synopsis
- Gaucher disease (GD) is a genetic lysosomal storage disorder caused by a deficiency in the enzyme glucocerebrosidase (GBA1), and its diagnosis typically employs assays that can be compromised by background activity from other enzymes.
- Researchers have developed a selective fluorogenic substrate called 6-O-alkyl-4MU-β-Glc, which effectively targets GBA1 and avoids interference from other enzymes, making it suitable for diagnosing GD.
- Additionally, analyses of spleen samples from GD patients revealed increased levels of acylated and regular glycosyl lipids, highlighting a potential link between plant-derived glycosyl phytosterols and the disease, raising questions about their role in developing conditions like Parkinson's
Article Synopsis
- The BIONYX trial is the first to compare the long-term outcomes of the Onyx durable polymer-coated zotarolimus-eluting stent (ZES) and the Orsiro biodegradable-polymer sirolimus-eluting stent (SES) in a diverse patient group, including those with diabetes.
- After a 5-year follow-up of nearly all participants, the results indicated no significant difference in the rate of target vessel failure (TVF) between the two stents (12.7% for Onyx vs. 13.7% for Orsiro).
- However, patients treated with Onyx ZES aged 75 years and older showed lower rates of TVF compared to those with Orsiro
Objective: We sought to evaluate accurate and reproducible detection of Myxobolus cerebralis (Mc), the causative agent of whirling disease, by using nested polymerase chain reaction (nPCR) and three previously established real-time quantitative PCR (qPCR) assays: K18S (Kelley 18S), C18S (Cavender 18S), and Hsp70 (heat shock protein 70). We used a "fit for purpose" approach combined with intra- and interlaboratory testing to identify a molecular testing method that would be equivalent to the currently accepted nPCR procedure for Mc.
Methods: Assay performance was compared using a combination of intra- and interlaboratory testing that used synthetic gBlocks along with naturally and experimentally infected fish tissue.
Background And Aims: Previous studies in percutaneous coronary intervention (PCI) patients showed a higher 3-year adverse event risk, including all-cause mortality, in those with concomitant peripheral arterial disease (PADs). Ten-year data of mortality and causes of death are scarce. This analysis assessed PCI patients, treated with contemporary drug-eluting stents, the impact of concomitant PADs on very long-term mortality, and causes of death.
View Article and Find Full Text PDFArticle Synopsis
- * LEI-515 is a new MAGL inhibitor that only affects peripheral organs, increasing 2-AG levels without impacting the mouse brain, which could limit side effects.
- * In animal studies, LEI-515 reduced liver damage and pain from chemotherapy without the negative effects seen with other MAGL inhibitors, suggesting it could be a safer option for treating inflammation and pain.